Antibody-hyaluronic acid bioconjugates for localized treatment of chronic non-infectious uveitis
Ended Project Grant Awarded Last action
- Award ID
- R43EY032414
- Recipient
-
Valitor, Inc. UEI MAUBKJ5FZ2K5
- Awarding agency
-
National Eye Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $896,327
Award facts
- Assistance listing
- 93.867 Vision Research
- Completion date
- Originally
- Funding
-
- $597,043.07 Federal
- $299,284.00 Non-federal
- Place of performance
- Berkeley, CA 94710, USA
Award details come from USAspending.gov.
Description
- Abstract
- Uveitis is a group of diseases characterized by sight-threatening intraocular inflammation and responsible for roughly 5-10% of blindness cases worldwide. Uveitis flare-UPS can be caused by either an active infection or, in in the case of non-infectious uveitis (NIU), a dysregulated immune response including altered cytokine expression and processing. Thus, there is an urgent and unmet need for more effective treatments. The standard first line therapies for chronic NIU are corticosteroids delivered either topically, systemically, or locally through intravitreal injections or implants. However, long-term use of these treatments is associated with serious side effects. Alternative anti-inflammatory therapeutics are often used to minimize these side-effects and inhibition of the pro-inflammatory cytokine, tnfa has become a key approach. Systemic delivery of tnfa inhibitors is effective but costly and carries a risk of side-effects from long-term use. Valitor, INC. Is developing protein-polymer therapeutics to overcome the vision-threatening effects of chronic ocular inflammation with substantially fewer systemic side effects by enabling intravitreal delivery of a biologic anti-tnfa therapy. We have conjugated single-domain anti-tnfa antibodies (VHH) to linear chains of the natural biopolymer hyaluronic acid to generate multivalent anti-tnfa conjugates (anti-tnfa MVP) that are substantially larger than any other drugs currently delivered by intravitreal injection. In our previous studies, we verified that the large sizes of our mvps are sufficient to substantially reduce their clearance rate out of the vitreous, thereby providing a sustained treatment effect to inhibit intraocular tnfa. Thus, our strategy for sustained anti-tnfa therapy has the potential to improve the long-term efficacy, safety, and cost efficacy of anti-tnfa treatment. The overall objective of this phase i sbir project is to verify that our anti-tnfa mvps exhibit a rapid onset and durable anti-inflammatory treatment for chronic non-infections uveitis. In specific aim #1, we will evaluate the ability of an anti-tnfa MVP to generate a rapid anti-inflammatory response compared to that of a corticosteroid. In specific aim #2, we will verify the anti-inflammatory durability of our anti-tnfa MVP to that of a clinically available tnfa inhibitor. The results of this project will be used to continue the development of our anti-tnfa MVP drug product and contribute to a productive pre-IND meeting to confirm the additional testing that required for our IND submission.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$1,525 | $0 | |
| Amendment | $299,284 | $0 | |
| Original award | $299,284 | $299,284 |
Quick answers
Who received award R43EY032414?
R43EY032414 was awarded to Valitor, Inc. by National Eye Institute (National Institutes of Health) on July 1, 2021.
How much is award R43EY032414 worth?
$896,327 has been obligated on R43EY032414: $597,043 in federal funding and $299,284 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award